2021 Advance Notice Elevates EDS Use, Leaves Out ESRD

The biggest news out of CMS’s Jan. 6 release of Part I of the 2021 Advance Notice may be that there was no news. As expected, CMS proposed continuing to phase out risk score data based on diagnoses contained in the legacy Risk Adjustment Processing System (RAPS) and increasing the use of encounter data that still vexes some Medicare Advantage organizations. But the document left out any mention of possible payment revisions for the expected influx of MA enrollees with end-stage renal disease (ESRD) next year, raising the question of when (and how) CMS might address a payment structure that is seen as inadequate by some industry stakeholders.

This is the third year CMS is publishing the Advance Notice of Methodological Changes for MA Capitation Rates and Part D Payment Policies in two parts, thanks to the 21st Century Cures Act (signed into law in 2016) requiring that any proposed changes to the CMS Hierarchical Condition Category (HCC) risk adjustment model have a 60-day comment period.

© 2024 MMIT
Lauren Flynn Kelly

Lauren Flynn Kelly Managing Editor, Radar on Medicare Advantage

Lauren has been covering health business issues, including drug benefits and specialty pharmacy, for more than a decade. She served as editor of Drug Benefit News (the predecessor to Radar on Drug Benefits) from 2004 to 2005 and again from 2011 to 2016, and now manages Radar on Medicare Advantage. Lauren graduated from Vassar College with a B.A. in English.

Related Posts

achp-logo
April 18

ACHP: Final Rule Checks ‘Untethered’ Agent, Broker Fees Impacting Competition

READ MORE
businessman-viewing-news-update-journalism-headline-on-a-laptop
April 18

News Briefs: UnitedHealth Reaffirms Full-Year Earnings Guidance Despite Cyberattack Impact

READ MORE
older-black-man
April 18

How Does MA Plan Design Impact Enrollment, Equity?

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today